Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds industry-leading growth potential as the company is launching several new blockbusters and patent losses are fading.
Lilly's strong leadership in weight-loss drugs should drive industry-leading growth with approved drugs and well-positioned next-generation weight-loss drugs in the pipeline.
The risks to success for Alzheimer’s drug donanemab remain high both in clinical development and insurance coverage.
|
Metric
|
LLY
|
NVO
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 96.74 | 50.73 | 61.25 |
Price/Book Value | 63.57 | 45.81 | 8.34 |
Price/Sales | 22.74 | 18.54 | 5.51 |
Price/Cash Flow | 94.52 | 43.41 | 19.38 |
|
Metric
|
LLY
|
NVO
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.68 | 0.49 | 0.68 |
Current Ratio | 1.35 | 0.70 | 1.25 |
Interest Coverage | 14.11 | 45.82 | 3.97 |
|
Metric
|
LLY
|
NVO
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 11.20% | 30.91% | 5.22% |
Return on Equity (Normalized) | 57.69% | 95.22% | 13.56% |
Return on Invested Capital (Normalized) | 20.65% | 73.76% | 8.29% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Johnson & Johnson
JNJ
| Jpzzbdwm | Crdy | $358.9 Bil | |||
| Merck & Co Inc
MRK
| Fscxfwksx | Qzsq | $336.8 Bil | |||
| AbbVie Inc
ABBV
| Brjpwlql | Njn | $305.0 Bil | |||
| AstraZeneca PLC ADR
AZN
| Gnxctycr | Wdqw | $246.7 Bil | |||
| Roche Holding AG ADR
RHHBY
| Gqgfsgwfny | Jmz | $230.4 Bil | |||
| Novartis AG ADR
NVS
| Lphtrshy | Gzf | $219.0 Bil | |||
| Amgen Inc
AMGN
| Cvqxjkmjc | Vxpz | $171.3 Bil | |||
| Pfizer Inc
PFE
| Zgypybj | Rfq | $160.7 Bil | |||
| Sanofi SA ADR
SNY
| Dngjddlk | Bpqk | $122.0 Bil |
:quality(80)/s3.amazonaws.com/arc-authors/morningstar/a90c659a-a3c5-4ebe-9278-1eabaddc376f.jpg)